1. The Effect of TNF and Non-TNF-Targeted Biologics on Body Composition in Rheumatoid Arthritis
- Author
-
Sandrine Malochet-Guinamand, Martin Soubrier, Marie Eva Pickering, Gaelle Vial, Sylvain Mathieu, Bruno Pereira, Marion Couderc, Céline Lambert, Anne Tournadre, CHU Clermont-Ferrand, Unité de Biostatistiques [CHU Clermont-Ferrand], Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), CHU Clermont-Ferrand-CHU Clermont-Ferrand, Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA), Unité de Nutrition Humaine (UNH), and Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Clermont Auvergne (UCA)
- Subjects
rheumatoid arthritis ,medicine.medical_specialty ,muscle ,medicine.medical_treatment ,Adipose tissue ,lcsh:Medicine ,Gastroenterology ,Article ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,fat ,medicine ,Mass index ,030212 general & internal medicine ,030203 arthritis & rheumatology ,body composition ,business.industry ,lcsh:R ,General Medicine ,medicine.disease ,3. Good health ,TNF inhibitor ,Rheumatoid arthritis ,Lean body mass ,Tumor necrosis factor alpha ,Composition (visual arts) ,Subcutaneous adipose tissue ,business ,biologic ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
Rheumatoid arthritis (RA) is associated with a decrease in lean mass and stability or even an increase in fat and ectopic adipose tissue. A few data are available on body composition changes under treatment, and data are still controversial. Body composition was assessed before initiation of biologic disease-modifying antirheumatic drug (bDMARD) and after 6 and 12 months of stable treatment. Eighty-three RA patients were included (75% of women, mean age 58.5 ±, 10.8 years) of whom 47 patients treated with TNF inhibitor (TNFi), 18 with non-TNF-targeted biologic (Non-TNFi), and 18 with conventional DMARD (cDMARD) alone. In the TNFi group, total lean mass, fat-free mass index, and skeletal muscle mass index significantly increased at 1 year. An increase in subcutaneous adipose tissue (SAT) without change for the visceral or body fat composition was associated. These changes were associated with an improvement in strength and walking test. In non-TNFi or cDMARD groups, no significant changes for body composition or muscle function were observed at 1 year. However, no significant differences for treatment x time interaction were noted between group treatments. In active RA patients starting first bDMARD, treatment with TNFi over 1 year was associated with favorable changes of the body composition and muscle function.
- Published
- 2021
- Full Text
- View/download PDF